Produktname:9-Bromo-5,6-dihydro-2-iodo-imidazo[1,2-d][1,4]benzoxazepine

IUPAC Name:12-bromo-4-iodo-9-oxa-3,6-diazatricyclo[8.4.0.0²,⁶]tetradeca-1(14),2,4,10,12-pentaene

CAS:1282516-69-1
Molekulare Formel:C11H8BrIN2O
Reinheit:95%+
Katalognummer:CM152652
Molekulargewicht:391.01

Packungseinheit Verfügbarer Vorrat Preis($) Menge
CM152652-100mg in stock ƎțƎ
CM152652-250mg in stock ưǜư
CM152652-10g in stock ưȬŴț
CM152652-25g in stock țưNJȬ
CM152652-100g in stock ƎƦNJŴǜ

Nur für den Einsatz in Forschung und Entwicklung..

Anfrage-Formular

   refresh    

Produkt-Details

CAS-Nr.:1282516-69-1
Molekulare Formel:C11H8BrIN2O
Schmelzpunkt:-
SMILES-Code:IC1=CN2CCOC3=CC(Br)=CC=C3C2=N1
Dichte:
Katalognummer:CM152652
Molekulargewicht:391.01
Siedepunkt:
Mdl-Nr.:MFCD22690733
Lagerung:2-8°C

Category Infos

Imidazoles
Imidazole is an important five-membered nitrogen-containing heterocyclic compound. Among the numerous heterocyclic compounds, imidazole and its derivatives are regarded as a unique and multifaceted scaffold material due to their diverse applications in industrial, organic and pharmaceutical chemistry. Imidazoles interact in different ways with many therapeutic targets, enzymes and receptors in biological systems and thus exhibit a wide range of biological activities. In particular, several imidazoles can be used as clinical drugs to treat various types of cancer with high therapeutic efficacy. Furthermore, imidazoles are one of the most critical segments in the field of anti-covid-19 virus drug discovery due to their ability to interact with active targets in living systems.
Imidazole Manufacturer
As a professional imidazole manufacturer, we can guarantee product quality and delivery time.our company has been committed to supply personalized product solutions to customers,pls consult us.

Column Infos

Inavolisib
Genentech’s Phase III results show that the Inavolisib (GDC-0077) treatment meets the primary end point in hormone receptor (HR)-positive, HER2-negative, PIK3CA-mutated Breast Cancer. The combination of Inavolisib with Palbociclib and fulvestrant improves the progression-free survival (PFS) in the first line. Inavolisib is a potent selective inhibitor of PI3K alpha (PI3Kα) that binds to the ATP-binding site of p110α, and promotes the degradation of mutated p110α.